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It has been 15 years since the Human Genome project announced
that it had sequenced 90% of the human genome. It took another three
years until they announced the successful completion of the project,
having sequenced 99% of the human genome (The Human Genome
Project, 2003). Compare that to today, where an individual's genome
can be sequenced in a matter of three days (Illumina Corp., 2015).
With those advances, it is now technically possible to create a patient
registry enabled by a patient's Complete Health Record, combining ge-
nomic data, the vast amount of data available through Connected Med-
ical Devices, the ever increasing number of personal ﬁtness devices
(through the Internet of Things), along with data from the electronic
medical record (EMR) and other types of available patient data. One
would think that the insights gained from the Complete Health Record
would solve a wide range of health problems (see Fig. 1). But here is
where the problem of improving patient care through translationalen access article under the CC BY-NCmedicine and the problems of big data intersect: the problem is not
(necessarily) in the integration of the data: as with all big data prob-
lems, the problem is one of availability and analysis, in the ﬁnding and
understanding of signals, trends, causal (and not corollary) relation-
ships, and then turning those insights into actionable information.
To understand how to overcome these issues, and the truly dis-
ruptive technology that I believe lies on the horizon, we'll approach
this review in three parts: a look at the development of the concept of
“big data”, a discussion of the hindrances in applying big data tech-
niques in our environment today and then a look into the future, the
concept of the “Complete Health Record” and how that may change
the very nature of translational medicine.
2. The evolution of Big Data
When I started working in this industry in the late 1980s, running
statistical analyses against large data sets on massively parallel-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. The Complete Health Record - Includes all the health information about a patient,
not just what is in the EMR.
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ber of available processors) as it was about the sheer volume of data.
How long would the computing job run? When would we need to
switch tapes or disks to load in more data? Consider the CrayY-MP
C90 supercomputer, state of the art for crunching data in 1991, had 16
CPUs, with 2 Gb of central memory, ran at 16 Gigaﬂops and had 16 Gb
of SSD storage (Cray Research, Inc., 1991). My current laptop has more
raw processing power, central memory and storage than that Cray!
In the late 1990s came the availability of multiple networked PC
processors, referred to as “High Performance Computing (HPC)” with
around the same amount of processing power of a Cray, but with hun-
dreds of terabytes of storage and a considerably lower cost. And while
organizations were busy implementing HPC clusters and networking
vast amounts of data, vendors started offering Software as a Service
(SaaS), which itself evolved into storing vast amounts of data in the
“Cloud”. The issue evolved from technical limitations of physical storage
or processing power to such questions as: “How much compute power
and storage space can be purchased?” and “How quickly can the system
be spun up?”
And the big question: how to integrate the data.
In the early 2000s, while SaaS and the Cloud were evolving, came a
focus on data interoperability and integration standards. HL7. CDISC.
Continuaa Alliance. SAFE BioPharma. IHE. All focused on enabling inter-
operability and integration. In 2006, I was evangelizing the concept of
standards in conference presentations focused on encouraging organi-
zations to embrace standards, citing the beneﬁt “Do you have your
next blockbuster drug in your discarded portfolio and don't know it?”
The implication of that statement is by using standards you can have
access to data, and views across data, which were previously hidden,
stored in individual silos. And that once this data was made available
to awider range of researchers, additional insights could be gained, sim-
ply through the mindshare of additional researchers and the possibility
of new ways of looking at data.
When it comes to these standards, we've largely arrived at a place
where it is possible to realize that vision. By the time of this article in
2015, the industry has largely moved from evangelizing the need for
developing standards to implementing mature standards that have
been around for years, easing integration to a degree not possible just
a decade ago.
3. Big Data and Translational Medicine today
And while we now have the ability to process and store massive
amounts of data, and the standards and technologies that enable theintegration of that data, there are still problems in Big Data in general
and in applying Big Data techniques to Translational Medicine more
speciﬁcally that hinder the vision of ﬁnding those critical insights.
Critics of Big Data use the oft cited phrase common tomany informa-
tion technology initiatives: the problemwith Big Data is about the right
data, delivered to the right people at the right time (ForteWares, 2014).
I've personally used this phrase for years, mostly when speaking about
user experience and user interfaces, but it is equally applicable to Big
Data, and especially when applied to Translational Medicine.
Let's use that paradigm to test a common application of translational
medicine: the patient registry.
3.1. Right data
Not only questions the veracity of the data, but the applicability of
the data and (perhaps most importantly) the accessibility of the data.
• If the registry includes data from ﬁtness trackers, was the data really
generated by that patient?
• For registries driven by electronic medical records, is the information
up to date?
• Is the right information captured for the type of study you are trying to
recruit?
• Do you have access? While you may have good EMR data sets, have
you formed agreements with ﬁtness data providers like FitBit or pa-
tient focused data aggregators such as 23AndMe or PatientsLikeMe?
Have you solved the problem of correlating patients from those ser-
vices with the EMR data you already have?
3.2. Right person
When thinking about the right person, we need to think not only
about the analysts themselves, but also consider the analysis technology
that the analyst can use to provide insights.
• Do you have medical specialists on hand who understand all the
sources of data in the registry?
• Do you have technology that can pose questions in the right way,
interrogating data across domains, utilizing the CompleteMedical Re-
cord, and can look at relationships between genomic, ﬁtness, medical
records, and patient adherence? Across patients? Across populations?
3.3. Right time
One of the tenets of Big Data is an acknowledgement that the under-
lying data is rapidly changing.
• Can you ﬁnd patients to recruit for your trial, at precisely the right
point in that patient's health timeline, deﬁned by the interaction
between their recent ﬁtness, current adherence pattern, and current
medical record?
o Was there a life-event that negatively impacted a patient's adher-
ence pattern years ago, but not currently?
o Have you controlled for the patient's current adherence history in
the inclusion/exclusion criteria of a clinical trial?
Those are tough questions, not only showing how necessary it is to
use the Complete Health Record and Big Data analysis techniques to
drive insights, but also showing how difﬁcult it is to use patient regis-
tries if the concept of the Complete Health Record is not taken into
account.
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Yet there are emerging capabilities and trends which show using
Big Data analysis techniques against the Complete Health Record, or
at least real-world data, can drive insights not possible a few years
ago.
Let's consider the art of the possible, from some real world use cases
that I've personally witnessed:
• A biopharmaceutical company has a drug going off patent in ﬁve
years. By interrogating large EMR data sets, across geographies, with
tens of millions of patient lives, other co-indications for that drug
are detected through improvement in symptomology. These co-
indications are in heretofore unstudied therapeutic areas, completely
unrelated to the original FDA approval. The improvements in sympto-
mology are detected by the analysis, not necessarily looking for a specif-
ic symptom, but using signal detection to look across indications, across
symptoms.
• When planning large Phase III studies, or groups of studies, it is possible
to take patient registry data, EMR data sets, and operational data from
previous studies to better plan the protocol, understanding the proﬁle
of the patient AND the proﬁle of the investigational site .In the end,
this develops a better protocol, greatly enhances patient recruitment
and leads to fewer protocol amendments. The end effect is saving
time andmoney in the execution of the trial while ending up with bet-
ter data for your submission. The best part: it is all done graphically, en-
abling the user to focus on the questions to ask the data, and not onhow
to format the questions or the underlying data set.
5. Emerging technologies
There are examples of emerging technologies and services that indi-
cate there may well be solutions to some of the analysis issues. Compa-
nies such as Tamr andMark Logic are taking novel approaches to solving
the right data, right person, right time problems.
Tamr (http://www.tamr.com) utilizes a curated workﬂow along
with machine learning. A curation workﬂow identiﬁes and maps data
the system doesn't understand. The system then learns from that
curation, applying machine learning algorithms, reducing curation in-
tervention in subsequent data sets. Tamr offers an adapter for CDISC, en-
abling the conversion, validation and packaging of clinical study data
into CDISC format (Tamr Inc., 2015).
Mark Logic (http://www.marklogic.com) is paving theway in Enter-
prise NoSQL solutions, which enable integration, storage, analysis and
search across multiple, complex data-types, including both structured
and unstructured data (Mark Logic, 2015).This enables researchers to
ask new questions as opposed to simply testing hypothesis.
6. The drive to the Complete Health Record
While the technology to drive insights from disparate sources and
types of information, to drive the right data to (and for) the right person
at the right time is certainly evolving in a positive direction, perhaps the
greatest problem faced in driving insights using Big Datamethodologies
is theproblemof availability, speciﬁcally the availability of the Complete
Health Record.
Consider the different types of data enumerated in Fig. 1. Many of
those data types are available for the purposes of building patient regis-
tries: Provider Focused Electronic Medical Records (EMR), Connected
Medical Devices, Genomic Information. But a vast amount of data is
not available in a single place for the patient, let alone for research pur-
poses. Nor is it certain that the patient has access to ‘all’ their informa-
tion, even though it is “theirs”. Indeed, this raises the question of
ownership (which we won't deal with in this article): is the patient's
data theirs or is it the physician/providers data?From the researcher standpoint,where can they get data sets that in-
clude not just the EMR or Genomic information commonly in a patient
registry, but also gain insights from patient created data, or data created
from the increasing number of Connected Medical Devices, not just the
devices provided by the provider or physician?
Is the notion of using the Complete Health Record in patient regis-
tries, to drive a complete view of the patient, even possible?
The possibility does exist to build patient registries and other
research data sets from the Complete Health Record of a patient, but as
an industry we havework to do to get us there. Many countries have cre-
ated centralized medical records. In the US, we have been moving to-
wards connecting health records, even if only regionally. But even those
efforts only connect Provider Focused data and completely ignore Con-
nected Medical Devices and patient generated data.
There are existing technologies which allow the collection of patient
focused as well as provider focused data. Microsoft's HealthVault
(Microsoft, 2015) enables patients to pull together their Complete
Health Record, including data not just from provider-focused EMR and
medical devices, but also pharmacy information, patient focused Con-
nected Medical Devices, ﬁtness information and a host of other patient
focused health data (Full Disclosure: the author served as CTO for
Microsoft's Life Sciences Industry Unit from 2007 to 2013).
When provider organizations adopt this technology, integrating it
with their EMR, it opens a door for greater availability of data, with
the possibility of access to patient focused health data and not just pro-
vider focused health data. But that is also the downside of this approach:
the requirement for the provider to enable access to their EMR, even if
only through the download of an HL7 CCD (Continuity of Care Docu-
ment) and the requirement for the patient to grant access to that data.
Microsoft places a heavy (but necessary) emphasis on privacy, requiring
the patient to opt-in to the use of their data. If the patient is unaware of
the ability to use their data for research purposes, if the apps don't exist
to take advantage of that patient data, then that Complete Health Re-
cord becomes useful only for the patient.
A different approach has been taken by Apple with their ResearchKit
(Apple Inc., 2015). While the details and uses of the Research Kit are
emerging at the time of this article, early uses show promise. The ap-
proach taken by Apple with their ResearchKit is to enable the creation
of apps speciﬁcally for collecting research data. Participating research or-
ganizations can contribute to the open source framework, create apps to
gather data from patients and then publicize those apps within their tar-
get patient communities. Themore patients that contribute, the richer the
data. This approach has the downside of not capturing provider-focused
data, nor the inability to integrate EMR data (at least as of this writing),
but has the upside of gathering data from increasing numbers of patients.
What's needed is a combination of these approaches. An approach
where research organizations can create apps, focused on collecting
not just the individual data types they create or utilize, but apps that
can access all the different types of data available to the patient, includ-
ing provider-focused health data. Apps that take into account not just
the immediate data-points researchers THINK are of interest, but apps
that have access to the vast array of patient data, have access to the
patient's Complete Health Record, the intersection of EMR, PHR, Con-
nected Medical Devices, pharmacy information, ﬁtness information
and patient behavioral data.
These combined approaches enable the “holy grail” of Big Data in
Translational Medicine: the ability to comb through data, to identify in-
sights, enable signal detection, and ﬁnd patterns that can create new
and novel research questions rather than the traditional method of cre-
ating hypothesis and then generating the questions to test those
hypotheses.
7. Conclusion
The standards exist for integrating both provider focused andpatient
focused health data, for the most part. The technology exists, and more
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the-box questions of the data, questions that weren't envisioned when
they created their initial data-sets. Platforms exist for the capturing of
patient focused data and storing that data alongside provider focused
EMR data.
What's needed to solve the problems with Big Data in Translational
Medicine is a combination of approaches: research focused apps com-
bined with access to a population of patients Complete Health Records,
enabling greater numbers of patients to contribute and allowing
researchers to have access to complete, all-encompassing health data,
which will drive insights and the ability to detect patterns, rather than
simply testing hypothesis, ultimately driving more timely and targeted
therapies to market.
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